舒尼替尼致肾病综合征文献分析

张旭升; 刘鹏; 梁霄; 沈承武; 卢翠翠

doi:10.6039/j.issn.1001-0408.2023.14.15

您当前的位置：

首页 >

文章列表页 >

舒尼替尼致肾病综合征文献分析

药物与临床 | 更新时间：2023-07-24

- 舒尼替尼致肾病综合征文献分析
- Literature analysis of sunitinib-induced nephrotic syndrome
- 中国药房 2023年34卷第14期页码：1739-1743
- 作者机构：
  
  山东第一医科大学附属省立医院药学部，济南　250021
- 作者简介：
  
  硕士研究生。研究方向：临床药学。电话：0531-78776461。E-mail：xusheng2022123@163.com
  副主任药师，硕士生导师，博士。研究方向：临床药学。电话：0531-78776461。E-mail：cece2021@163.com
- 基金信息：
  
  山东省药品化妆品不良反应监测哨点课题(2022SDADRKY01);山东省医学会临床药学科研专项资金项目(YXH2022ZX001);医院药物警戒研究协作组医院药学科研专项课题(DRM2022018)
- DOI：10.6039/j.issn.1001-0408.2023.14.15
  中图分类号： R979.1;R969.3
- 纸质出版日期：2023-07-30，
  
  收稿日期：2022-12-05，
  
  修回日期：2023-06-16，
扫描看全文
张旭升,刘鹏,梁霄等.舒尼替尼致肾病综合征文献分析 ^Δ[J].中国药房,2023,34(14):1739-1743.

ZHANG Xusheng,LIU Peng,LIANG Xiao,et al.Literature analysis of sunitinib-induced nephrotic syndrome[J].ZHONGGUO YAOFANG,2023,34(14):1739-1743.
张旭升,刘鹏,梁霄等.舒尼替尼致肾病综合征文献分析 ^Δ[J].中国药房,2023,34(14):1739-1743. DOI： 10.6039/j.issn.1001-0408.2023.14.15.

ZHANG Xusheng,LIU Peng,LIANG Xiao,et al.Literature analysis of sunitinib-induced nephrotic syndrome[J].ZHONGGUO YAOFANG,2023,34(14):1739-1743. DOI： 10.6039/j.issn.1001-0408.2023.14.15.

摘要

目的

分析舒尼替尼致肾病综合征的临床特点，为临床安全用药提供参考。

方法

计算机检索中国知网、维普网、万方数据、PubMed、Web of Science、Medline，收集舒尼替尼致肾病综合征的个案报道，对报告涉及的患者性别、年龄、原发疾病、用药情况、临床表现、治疗和转归等进行统计分析，检索时限均为建库起至2022年10月30日。

结果

共纳入文献15篇，涉及17例患者，其中男性10例、女性7例，平均年龄（59.35±15.72）岁。17例患者中，肾细胞癌10例、胃肠道间质瘤7例，均为有指征用药；15例患者记载了舒尼替尼的用药剂量，且均在药品说明书推荐范围内；9例患者为联合用药；服用舒尼替尼后至发生肾病综合征时间为21 d～52个月，其中11例为≤2年。13例患者的临床表现主要包括水肿、少尿、泡沫尿、体重增加、疲劳、劳累性呼吸困难等。8例患者在发生肾病综合征前出现了舒尼替尼诱发的其他不良反应，包括新发高血压或原有高血压恶化、手足综合征。肾活检主要表现为血栓性微血管病、局灶节段性肾小球硬化症和免疫复合物肾小球肾炎。所有患者均停用或减量使用舒尼替尼，并给予糖皮质激素、降压药等对症治疗，其中16例患者症状缓解，1例患者肾功能恶化并需要透析。6例患者再次使用了舒尼替尼，其中5例患者再次出现肌酐升高、大量蛋白尿等症。

结论

临床在使用舒尼替尼时，应定期监测患者肾功能，如果出现肾功能恶化、蛋白尿、水肿等症，需及时完善相关检查并尽早干预，同时警惕再次使用舒尼替尼后肾病综合征的复发。

Abstract

OBJECTIVE

To analyze the clinical characteristics of nephrotic syndrome induced by sunitinib， and to provide reference for clinical rational drug use.

METHODS

Retrieved from CNKI， VIP， Wanfang data， PubMed， Web of Science and Medline， case report about sunitinib-induced nephrotic syndrome were collected from the inception to Oct. 30th， 2022. Those case reports were analyzed statistically in terms of gender， age， primary disease， drug use， clinical manifestations， treatment and outcome.

RESULTS

A total of 15 pieces of literature were collected and 17 patients were involved， including 10 males and 7 females. The average age of patients was （59.35±15.72） years. Among 17 patients， there were 10 patients with renal cell carcinoma and 7 patients with gastrointestinal stromal tumor， all of whom received evidence-based medication； the dosage of sunitinib in 15 cases was recorded， and all of them were within the recommended range of the instructions； 9 patients received combined therapy； the time from sunitinib application to the occurrence of nephrotic syndrome was 21 days-52 months， of which 11 cases were ≤2 years. The clinical manifestations in 13 patients were described， including edema， oliguria， foamy urine， weight gain， fatigue， dyspnea on exertion， etc. Eight patients had other adverse reactions induced by sunitinib before suffering from nephrotic syndrome， including new hypertension or worsening of original hypertension， and hand-foot syndrome. Renal biopsy mainly manifested as thrombotic microangiopathy， focal segmental glomerular sclerosis and immune complex glomerulonephritis. Sunitinib withdrawal or dosage reduction was adopted in all patients， and they were given symptomatic treatment such as glucocorticoids and antihypertensive agents. Symptoms of 16 patients were improved， and renal function of one patient deteriorated and hemodialysis was started. Sunitinib was re-challenged in 6 patients， elevated creatinine and substantial proteinuria recurred in 5 patients.

CONCLUSIONS

In clinical use of sunitinib， it is advisable to periodically monitor renal function. In case of deterioration of renal function， albuminuria， edema， etc.， relevant examinations should be implemented in time， and symptomatic intervention should be taken as soon as possible. Besides， we should be alert to the recurrence of nephrotic syndrome after sunitinib rechallenge.

关键词

舒尼替尼药品不良反应肾病综合征文献分析

Keywords

adverse drug reactionnephrotic syndromeliterature analysis

references

GAN H K，SERUGA B，KNOX J J. Sunitinib in solid tumors[J]. Expert Opin Investig Drugs，2009，18（6）：821-834.

KASSEM M G，MOTIUR RAHMAN A F M，KORASHY H M. Sunitinib malate[J]. Profiles Drug Subst Excip Relat Methodol，2012，37：363-388.

TAMADA S，KONDOH C，MATSUBARA N，et al. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma：outcomes of Japanese patients enrolled in the randomized，phase Ⅲ，open-label KEYNOTE-426 study[J]. Int J Clin Oncol，2022，27（1）：154-164.

CHEN Y S，CHEN C L，WANG J S. Nephrotic syndrome and acute renal failure apparently induced by sunitinib[J]. Case Rep Oncol，2009，2（3）：172-176.

国家食品药品监督管理局药品安全监管司，国家药品不良反应监测中心.药品不良反应报告和监测工作手册[M].北京：国家药品不良反应监测中心，2012：49-51.

ROLLEMAN E J，WEENING J，BETJES M G H. Acute nephritic syndrome after anti-VEGF therapy for renal cell carcinoma[J]. Nephrol Dial Transplant，2009，24（6）：2002-2003.

COSTERO O，PICAZO M L，ZAMORA P，et al. Inhibition of tyrosine kinases by sunitinib associated with focal segmental glomerulosclerosis lesion in addition to thrombotic microangiopathy[J]. Nephrol Dial Transplant，2010，25（3）：1001-1003.

JHAVERI K D，FLOMBAUM C D，KROOG G，et al. Nephrotoxicities associated with the use of tyrosine kinase inhibitors：a single-center experience and review of the literature[J]. Nephron Clin Pract，2011，117（4）：c312-c319.

LIU Y C，CHANG P M，LIU C Y，et al. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma[J]. Jpn J Clin Oncol，2011，41（11）：1277-1281.

TAKAHASHI D，NAGAHAMA K，TSUURA Y，et al. Sunitinib-induced nephrotic syndrome and irreversible renal dysfunction[J]. Clin Exp Nephrol，2012，16（2）：310-315.

TURAN N，BENEKLI M，OZTURK S C，et al. Sunitinib and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor[J]. Ann Pharmacother，2012，46（10）：e27.

PALLOTTI M C，PANTALEO M A，NANNINI M，et al. Development of a nephrotic syndrome in a patient with gastrointestinal stromal tumor during a long-time treatment with sunitinib[J]. Case Rep Oncol，2012，5（3）：651-656.

JHA P K，VANKALAKUNTI M，SIDDINI V，et al. Sunitinib induced nephrotic syndrome and thrombotic microangiopathy[J]. Indian J Nephrol，2013，23（1）：67-70.

RUEBNER R L，COPELOVITCH L，EVAGELIOU N F，et al. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy：case series and review of the literature[J]. Pediatr Nephrol，2014，29（5）：863-869.

QUINTYNE K I，NEENAN T，CASSERLY L，et al. Uncommon side effect with a commonly used targeted agent：sunitinib-induced nephrotic syndrome in a patient with metastatic renal cell carcinoma[J]. BMJ Case Rep，2014，2014：bcr2013201183.

吴小芳，徐缓，李孜. 1例舒尼替尼致肾脏血栓性微血管病变及肾病综合征报道[J]. 临床药物治疗杂志，2019，17（10）：85-89.

HAKSÖYLER V，PAYDAŞ S. An interesting case：sunitinib-induced microangiopathic hemolytic anemia and nephrotic syndrome[J]. Turk J Haematol，2021，38（2）：163-165.

ZONOOZI S，PALMER M，URSINA T，et al. Worsening membranous nephropathy in a patient with GIST treated with sunitinib[J]. BMJ Case Rep，2021，14（8）：e243567.

NIETO-RÍOS J F，GARCÍA-PRADA C A，ARISTIZABAL-ALZATE A，et al. Nephrotic syndrome as a manifestation of thrombotic microangiopathy due to long-term use of sunitinib[J]. Nefrologia（Engl Ed），2022，42（6）：722-726.

GEORGE B A，ZHOU X J，TOTO R. Nephrotic syndrome after bevacizumab：case report and literature review[J]. Am J Kidney Dis，2007，49（2）：e23-e29.

CHOUEIRI T K，POWLES T，BUROTTO M，et al. Nivo-lumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma[J]. N Engl J Med，2021，384（9）：829-841.

KOLLMANNSBERGER C，BJARNASON G，BURNETT P，et al. Sunitinib in metastatic renal cell carcinoma： recommendations for management of noncardiovascular toxicities[J]. Oncologist，2011，16（5）：543-553.

MOTZER R J，HUTSON T E，TOMCZAK P，et al. Ove-rall survival and updated results for sunitinib compared with interferon Alfa in patients with metastatic renal cell carcinoma[J]. J Clin Oncol，2023，41（11）：1965-1971.

KHANNA R. Clinical presentation & management of glomerular diseases：hematuria，nephritic & nephrotic syndrome[J]. Mo Med，2011，108（1）：33-36.

KIM E，KOO Y J，LEE D H. Bevacizumab-associated nephrotic syndrome in a woman with unilateral renal age-nesis[J]. Am J Ther，2020，28（3）：368-369.

GUREVICH F，PERAZELLA M A. Renal effects of anti-angiogenesis therapy：update for the internist[J]. Am J Med，2009，122（4）：322-328.

GOLDBERG R J，NAKAGAWA T，JOHNSON R J，et al. The role of endothelial cell injury in thrombotic microangiopathy[J]. Am J Kidney Dis，2010，56（6）：1168-1174.

PATEL T V，MORGAN J A，DEMETRI G D，et al. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib[J]. J Natl Cancer Inst，2008，100（4）：282-284.

OLAYA-C M，GARRIDO M，HERNANDEZ-LOSA J，et al. The umbilical cord，preeclampsia and the VEGF family[J]. Int J Womens Health，2018，10：783-795.

EDDY A C，BIDWELL G L，GEORGE E M. Proan-giogenic therapeutics for preeclampsia[J]. Biol Sex Differ，2018，9（1）：36.

中国医促会泌尿健康促进分会，中国研究型医院学会泌尿外科学专业委员会. 肾癌分子靶向药舒尼替尼用药安全共识[J]. 现代泌尿外科杂志，2020，25（10）：862-869.

HOUK B E，BELLO C L，MICHAELSON M D，et al. Exposure-response of sunitinib in metastatic renal cell carcinoma（mRCC）：a population pharmacokinetic/pharmacodynamic（PKPD）approach[J]. J Clin Oncol，2007，25（18_suppl）：5027.

HENG D Y C，KOLLMANNSBERGER C. Sunitinib[J]. Recent Results Cancer Res，2010，184：71-82.

Kidney Disease：Improving Global Outcomes （KDIGO）Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular di-seases[J]. Kidney Int，2021，100（4S）：S1-S276.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

肝癌合并HBV感染患者使用富马酸替诺福韦二吡呋酯致肾损伤1例并文献分析

临床药师参与1例左氧氟沙星致超敏反应的药学监护及文献分析

地舒单抗相关非典型骨折的文献分析

度普利尤单抗致眼部相关不良反应文献分析

ICU常用静脉药物配伍稳定性的文献分析